See more : Armada Acquisition Corp. I (AACI) Income Statement Analysis – Financial Results
Complete financial analysis of TRxADE HEALTH, Inc. (MEDS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TRxADE HEALTH, Inc., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
You may be interested
- Yuexiu Real Estate Investment Trust (YUXXF) Income Statement Analysis – Financial Results
- Ramkrishna Forgings Limited (RKFORGE.NS) Income Statement Analysis – Financial Results
- Silver Bear Resources Plc (SBR.TO) Income Statement Analysis – Financial Results
- We-R-You Corp. (WERU) Income Statement Analysis – Financial Results
- Sartorius Aktiengesellschaft (SOAGY) Income Statement Analysis – Financial Results
TRxADE HEALTH, Inc. (MEDS)
About TRxADE HEALTH, Inc.
TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O' Lakes, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.27M | 11.45M | 9.89M | 17.12M | 7.44M | 3.83M | 2.93M | 2.48M | 4.99M | 1.50M | 955.88K | 806.05K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 5.67M | 6.00M | 5.14M | 11.42M | 2.57M | 449.05K | 0.00 | 16.36K | 1.93M | 440.05K | 944.07K | 689.81K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.60M | 5.45M | 4.75M | 5.71M | 4.87M | 3.38M | 2.93M | 2.47M | 3.06M | 1.06M | 11.81K | 116.24K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 31.41% | 47.62% | 47.99% | 33.33% | 65.50% | 88.28% | 100.00% | 99.34% | 61.38% | 70.59% | 1.24% | 14.42% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.38M | 1.16M | 1.37M | 662.73K | 647.14K | 949.95K | 375.17K | 286.76K | 319.44K | 319.44K | 611.71K | 198.41K | 0.00 | 0.00 | 3.57K |
| General & Administrative | 8.48M | 7.05M | 8.81M | 7.49M | 4.38M | 2.35M | 2.27M | 3.30M | 3.70M | 2.11M | 2.10M | 266.95K | 28.50M | 0.00 | 5.16K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 147.63K | 355.12K | 374.62K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.48M | 7.05M | 8.81M | 7.49M | 4.38M | 2.35M | 2.27M | 3.45M | 4.05M | 2.49M | 2.10M | 266.95K | 28.50M | 24.77K | 5.16K |
| Other Expenses | 14.54K | 1.60M | -1.23M | 3.25M | 72.08K | 161.64K | 67.50K | 131.27K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.42K | 0.00 |
| Operating Expenses | 9.86M | 8.21M | 8.81M | 7.49M | 4.38M | 3.30M | 2.27M | 3.45M | 4.05M | 2.49M | 2.10M | 266.95K | 28.50M | 28.19K | 8.73K |
| Cost & Expenses | 15.54M | 14.20M | 13.96M | 18.90M | 6.94M | 3.75M | 2.27M | 3.47M | 5.98M | 2.93M | 3.04M | 956.76K | 28.50M | 28.19K | 8.73K |
| Interest Income | 4.20K | 20.99K | 23.59K | 29.39K | 53.23K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.20M | 336.21K | 23.59K | 29.39K | 53.23K | 57.54K | 157.06K | 151.50K | 130.14K | 4.15K | 7.28K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.05M | 194.70K | 138.91K | 102.52K | 94.73K | 87.62K | -395.10K | 8.67K | 3.80K | 4.80K | 3.99K | 2.63K | 0.00 | 0.00 | 0.00 |
| EBITDA | -13.72M | -1.85M | -5.15M | -2.51M | 660.55K | 96.65K | 288.98K | -984.03K | -133.27K | -2.00M | -2.08M | -148.09K | -28.50M | -28.19K | -8.73K |
| EBITDA Ratio | -74.89% | -22.18% | -52.11% | -9.80% | 8.88% | 6.36% | 24.92% | -39.65% | -19.70% | -95.35% | -217.60% | -18.37% | 0.00% | 0.00% | 0.00% |
| Operating Income | -7.26M | -2.76M | -5.29M | -1.78M | 565.82K | -87.62K | 395.10K | -984.03K | -987.05K | -1.43M | -2.08M | -150.71K | -28.50M | -28.19K | -8.73K |
| Operating Income Ratio | -87.80% | -24.08% | -53.51% | -10.40% | 7.61% | -2.29% | 13.48% | -39.65% | -19.77% | -95.67% | -218.02% | -18.70% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.46M | -362.72K | -23.59K | -29.39K | -778.17K | 96.65K | -106.11K | -165.83K | -119.51K | -580.57K | -7.28K | 0.00 | 28.47M | 0.00 | 0.00 |
| Income Before Tax | -13.72M | -3.91M | -5.32M | -2.54M | -284.43K | 9.04K | 288.98K | -1.17M | -1.12M | -2.01M | -2.09M | -150.71K | -28.50K | 0.00 | 0.00 |
| Income Before Tax Ratio | -165.86% | -34.15% | -53.75% | -14.81% | -3.82% | 0.24% | 9.86% | -47.27% | -22.38% | -134.47% | -218.78% | -18.70% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 5.34M | 400.34K | -1.20M | 29.39K | 125.30K | -154.20K | -50.94K | 1.62M | 130.14K | 576.42K | 7.28K | 0.00 | 28.50M | 28.19K | 8.73K |
| Net Income | -17.84M | -4.31M | -4.11M | -2.57M | -409.73K | 9.04K | 288.98K | -2.76M | -1.12M | -2.01M | -2.09M | -150.71K | -28.50M | -28.19K | -8.73K |
| Net Income Ratio | -215.70% | -37.65% | -41.59% | -14.98% | -5.51% | 0.24% | 9.86% | -111.21% | -22.38% | -134.47% | -218.78% | -18.70% | 0.00% | 0.00% | 0.00% |
| EPS | -23.35 | -7.63 | -7.58 | -4.99 | -1.04 | 0.02 | 0.81 | -7.89 | -3.20 | -6.30 | -13.50 | -0.97 | -273.59 | -0.27 | -0.11 |
| EPS Diluted | -7.49 | -7.63 | -7.58 | -4.99 | -1.04 | 0.02 | 0.81 | -7.87 | -3.20 | -6.07 | -13.35 | -0.97 | -269.45 | -0.27 | -0.11 |
| Weighted Avg Shares Out | 764.06K | 564.86K | 542.45K | 513.71K | 395.27K | 388.43K | 355.06K | 349.64K | 349.64K | 319.37K | 154.91K | 154.91K | 104.16K | 105.76K | 81.20K |
| Weighted Avg Shares Out (Dil) | 2.38M | 564.86K | 542.45K | 513.71K | 395.27K | 388.43K | 378.74K | 350.50K | 349.64K | 331.46K | 156.69K | 154.91K | 105.76K | 105.76K | 81.20K |
TRxADE HEALTH to Report Second Quarter 2021 Financial Results on Monday, July 26th at 4:30 p.m. Eastern Time
TAMPA, FL / ACCESSWIRE / July 12, 2021 / TRxADE HEALTH, INC. (NASDAQ:MEDS) a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will release...
Short Squeeze Stocks: XELA, NEGG and 3 Other Stocks Experts Think Are Ready to Pop
Looking for the next AMC, retail investors are on the hunt for the next squeeze. Here are five short squeeze stocks to watch this week.
Why TRxADE HEALTH Shares Surged On Thursday
TRxADE HEALTH (NASDAQ: MEDS) shares are trading higher after the company's Bonum Health subsidiary signed a telemedicine service distribution deal with Big Y Pharmacy. Bonum Health will provide affordable telemedicine services to the patients of all Big Y pharmacies by...
MEDS Stock: The Big Bonum Health Deal That Has TRxADE Health Soaring Today
TRxADE Health (MEDS) stock is rocketing higher on Thursday following news of a telemedicine deal for subsidiary Bonum Health. The post MEDS Stock: The Big Bonum Health Deal That Has TRxADE Health Soaring Today appeared first on InvestorPlace.
MEDS Stock Price Increases Over 115%: Why It Happened
The stock price of TRxADE HEALTH INC. (NASDAQ:MEDS) increased by over 115% during intraday trading today.
Big Y and Bonum Health(TM) (TRxADE HEALTH Company) to deploy New Telemedicine Program
TAMPA, FL / ACCESSWIRE / July 1, 2021 / TRxADE HEALTH INC. (NASDAQ:MEDS) an integrated drug procurement, delivery, and healthcare platform, today announced that Bonum Health, a Digital Healthcare business subsidiary has signed a Telemedicine Service Distribution Deal with Big...
MEDS Soars After Vaccination App Debut
Ramped up Covid-19 vaccinations and easing restrictions across the globe are leading to strength in the travel sector.
MEDS Stock: The Huge Covid-19 News Lifting Trxade Health Today
Today, MEDS stock is soaring after the company announced the launch of an application designed to be a Covid-19 passport. The post MEDS Stock: The Huge Covid-19 News Lifting Trxade Health Today appeared first on InvestorPlace.
MEDS Stock Price: Over 49% Increase Pre-Market Explanation
The stock price of Trxade Health Inc (NASDAQ: MEDS) increased by over 49% pre-market. This is why it happened.
TRxADE HEALTH, INC. Announces Authorization of Stock Repurchase Program
TAMPA, FL / ACCESSWIRE / June 1, 2021 / TRxADE HEALTH, INC. (NASDAQ:MEDS), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., today announced...
Source: https://incomestatements.info
Category: Stock Reports